Whats new in ESC Guidelines for the management of valvular heart disease?
Authors:
Marian Branny
Authors‘ workplace:
Kardiovaskulární oddělení a Interní a kardiologické kliniky Fakultní nemocnice Ostrava a Lékařská fakulta Ostravské univerzity
Published in:
Vnitř Lék 2023; 69(E-3): 24-27
Category:
In Brief
doi:
https://doi.org/10.36290/vnl.2023.038
Overview
The article summarize the most important changes regarding the management of valvular heart disease, which have been made in the ESC Guidelines 2021. Based on the randomized clinical study data, which were recently published, the most frequent changes were done in terms of the choice of mode of intervention in the aortic and mitral valves as well as in the management of the antithrombotic therapy.
Keywords:
guidelines – aortic stenosis – aortic regurgitation – mitral regurgitation – mitral stenosis – percutaneous valve intervention – prosthetic heart valves – tricuspid regurgitation – tricuspid stenosis – valve disease – valve surgery – valvular heart disease
Sources
1. Vahanian A, Bayersdorf F, Praz F. 2021 ESC/EACTS Guidelines for the management of valvular heart disease, European Heart Journal. (2021)00,1-7.
2. Stone GW, Lindenfeld J, Abraham WT, COAPT Investigators. Transcatheter mitral‑valve repair in patients with heart failure. N Engl J Med. 2018;379:23072318.
3. Kang DH, Park SJ, Lee SA. Early surgery or conservative care for asymptomatic aortic stenosis. N Engl J Med. 2020;382:111-119.
Labels
Diabetology Endocrinology Internal medicineArticle was published in
Internal Medicine
2023 Issue E-3
Most read in this issue
- Finerenone
- Barakat syndrome
- Successful therapy of retroperitoneal fibrosis due to IgG4-related disease with rituximab, cyclophosphamide and glucocorticoids followed by maintenance therapy wit ritutixmab
- Whats new in ESC Guidelines for the management of valvular heart disease?